Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 3, 2003

View Archived Issues

Opioid/NMDA receptor antagonist combinations result in superadditive antinociception in rats

Preclinical evidence for anxiolytic activity of substance P antagonists

APAZA completes first phase I trial

CA4P plus radioimmunotherapy tested in phase I/II trial for colorectal cancer

Salmedix initiates phase II/III program for SDX-105 for NHL

European CPMP hands down positive opinion for Zevalin

Dainippon and Takeda discontinue development of antidiabetic agent

Peninsula and Takeda enter licensing agreement for TAK-599

Improved BMD in hypogonadal men treated with testosterone gel

Lower incidence of fractures and improved bone quality in patients treated with risedronate

Escitalopram may be a better therapeutic option than venlafaxine XR in major depression

Oral gallium formulation reported to reach therapeutic serum levels in Paget's disease

Protective effects reported for CS-003 against bronchoconstriction in asthma

Kava presents new IL-12 and TNF-alpha production inhibitors and their use

Novel cPLA2 inhibitors prepared and tested at Wyeth

Synthesis and use of new CRF1 antagonists described in recent patent

Three series of alpha7 nAChR agonists presented in patents

New acetyl-CoA carboxylase inhibitors identified by Pfizer researchers

Novel PPAR modulators discovered by Lilly scientists

Schering-Plough acquires rights to palonosetron

Enrollment completed in second pivotal trial of E2F decoy

IND filed for Numax phase I trial

Phase III protocol for STR in multiple myeloma agreed under SPA

Roche and Protein Design Labs restructure Zenapax alliance

FDA issues another approvable letter to Lilly for duloxetine

TKT to report one-year phase I/II results for I2S at upcoming genetics meeting

CERA: a potent and long-acting erythropoietic agent

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 4, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...